Status:
COMPLETED
Study Evaluating LXR-623 in Healthy Japanese Adults
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.
Eligibility Criteria
Inclusion
- Healthy, Japanese Males aged 20-45 years
Exclusion
- A history or active presence of clinically important medical disease
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00385489
Start Date
August 1 2006
End Date
September 1 2006
Last Update
August 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toshima-ku, Tokyo, Japan, 171-0014